Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Snap On Incorporated — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Snap On Incorporated trades at $404.38 (market cap $20.96B). The key difference: Snap On Incorporated is far larger — about 2.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Snap On Incorporated pays a 2.41% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | SNA | |
|---|---|---|
Market Cap | $8.04B | $20.96B |
Sector | Health | Technology |
52-Week High | $339.75 | $413.62 |
52-Week Low | $241.71 | $313.01 |
Enterprise Value | $7.85B | $20.48B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Snap-on Incorporated (SNA) trades at $401.11, down 0.21% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong profitability with a 19.6% net income margin and ROE of 17.83%, while recent acquisitions like Diesel Laptops for $100 million aim to expand heavy-duty diagnostics capabilities. Q1 2026 earnings missed expectations slightly, but Q2 results are anticipated.
Outlook remains positive with analyst consensus favoring Buy ratings (64.71%) and a $407.50 price target, though risks include margin pressures and muted growth forecasts. The stock offers stability with consistent dividends and share repurchases, but investors should monitor competitive and economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
